BrainsWay’s Growth Streak Just Got Harder To Ignore

In a field where innovation often outpaces market demand, neurostimulation company BrainsWay Ltd. has emerged as a rare exception. The company’s second-quarter 2026 results show a business that is scaling rapidly while generating meaningful margins.

Revenue climbed 35% year over year to $17.1 million, with Deep TMS system shipments hitting an impressive 125 units in the quarter – up 42% from last year. This growth is not a fluke; BrainsWay’s second straight quarter of near-35% revenue growth suggests that its business model is indeed catching on.

The company’s success has allowed it to generate significant operating income and cash flow, which have expanded its bottom line. Operating income jumped more than 300%, with operating margin expanding to 14% from just 5% a year earlier. Adjusted EBITDA rose an astonishing 141% to $3.5 million, with margins widening to 20%.

However, beneath this growth lies a complex web of factors driving BrainsWay’s expansion. The company points to continued growth in insurer coverage for its SWIFT accelerated Deep TMS protocol as a key driver, but the reimbursement picture remains uncertain. As BrainsWay invests further capital into minority stakes outside its core business, it risks diluting its focus on what has clearly been its most successful product – the Deep TMS system.

The company’s management has responded to these strong results by raising full-year revenue guidance to $68 million to $70 million and adjusted EBITDA guidance to $13 million to $14 million. While this growth is undeniably impressive, it also raises questions about what drives BrainsWay’s expansion strategy. The updated guidance is relatively modest compared to previous quarters’ beat expectations by a wide margin.

The company’s increasing focus on external investments – including minority stakes in Hopemark Health and Radial Health – poses risks that may not be immediately apparent. These partnerships promise growth in patient access, but they also divert capital away from BrainsWay’s core business. As of the latest reports, there is no clear financial detail on what returns these investments are generating.

BrainsWay’s success suggests that companies like it offer a unique model for success in neurostimulation. These results demonstrate how innovative technologies can scale and generate meaningful revenue without sacrificing margins. Yet, beneath this surface lies a more nuanced reality: as BrainsWay continues to grow, it must carefully balance the demands of expansion with the need to maintain focus on its core business.

The company’s investments outside its direct control – particularly those in reimbursement and patient access – will be crucial in determining whether this growth momentum can be sustained. For investors, these results offer a compelling reason to keep a close eye on BrainsWay’s future performance. But for the industry as a whole, they pose a more fundamental question: what does it take to scale effectively in neurostimulation?